Sangamo Therapeutics (SGMOQ) Cash from Financing Activities (2010 - 2025)

Sangamo Therapeutics' Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $14.8 million for Q4 2025.

• On a quarterly basis, Cash from Financing Activities rose 111.66% year-over-year to $14.8 million in Q4 2025; TTM through Dec 2025 was $70.7 million, a 149.32% increase from a year earlier, with the FY2025 full-year figure at $70.7 million, up 149.32% from the prior year.
• Cash from Financing Activities retreated to $14.8 million in Q4 2025 per SGMOQ's latest filing, from $19.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $43.8 million in Q3 2022 and bottomed at -$1.6 million in Q1 2022.
• The 5-year median for Cash from Financing Activities is $8.1 million (2023), against an average of $11.6 million.
• Across the five-year window, Cash from Financing Activities tumbled 110.29% in 2022 and soared 9560.1% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $2.1 million in 2021, then surged by 824.95% to $19.5 million in 2022, then slumped by 99.15% to $167000.0 in 2023, then jumped by 4086.23% to $7.0 million in 2024, then surged by 111.66% to $14.8 million in 2025.
• Per Business Quant, the three latest SGMOQ Cash from Financing Activities figures stand at $14.8 million (Q4 2025), $19.2 million (Q3 2025), and $28.6 million (Q2 2025).